文献速递结核与非结核分枝杆菌

M72/AS01E结核疫苗试验中结核分枝杆菌分离株的遗传特征

Genetic characterization of M. tuberculosis isolates from participants in a Phase 2b randomized trial evaluating the M72/AS01E tuberculosis candidate vaccine.
PubMed 文献 · J Infect Dis · 2026-08-28

结果显示两组间菌株谱系分布无 preferential 差异,未检出耐多药菌株,支持该候选疫苗继续开发。

要点

  • M72/AS01E组与安慰剂组结核分枝杆菌谱系分布无 preferential 差异。
  • 未检出耐多药结核分枝杆菌菌株。
  • M72/AS01E抗原组分编码基因pepA变异低而PPE18变异高,但变异分布无组间偏好。

核心结论

  • M72/AS01E组与安慰剂组间局部结核分枝杆菌菌株分布无 apparent preferential 差异,支持该候选疫苗继续开发。

研究设计与样本

  • 分离株来自痰样本,经DNA提取和测序评估谱系、抗生素耐药谱、遗传变异和基因组聚类。

主要发现

  • 未检测到耐多药菌株。
  • M72/AS01E抗原组分对应基因序列中pepA变异低而PPE18变异高,但M72/AS01E组与安慰剂组间变异分布无 apparent preferential 差异。
  • 聚类分析鉴定出10个包含超过1名参与者分离株的基因组聚类,提示复杂传播动态和个体内多菌株共感染可能。

临床怎么用

  • 该描述性分析提示M72/AS01E未选择特定结核分枝杆菌菌株进展为活动性结核,支持疫苗候选继续研发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy and safety of the M72/AS01E tuberculosis (TB) candidate vaccine were evaluated in the phase 2b randomized, placebo-controlled trial NCT01755598. In the trial, participants with Mycobacterium tuberculosis sensitization by a positive interferon-gamma release assay received either M72/AS01E or placebo (randomized 1:1) and were followed for 3 years. In this descriptive study, we genetically characterized M. tuberculosis isolates from participants who developed pulmonary TB during the trial to assess variability among isolates and evaluate the possibility of preferential progression from infection to active TB by certain strains in M72/AS01E and placebo recipients. METHODS: M. tuberculosis isolates were recovered from sputum samples and underwent DNA extraction and sequencing to assess lineage, antibiotic resistance profile, genetic variation, and genomic clusters. RESULTS: One hundred isolates (37 M72/AS01E, 63 placebo) were genetically characterized from 50 participants who developed microbiologically confirmed active pulmonary TB during the trial (20 M72/AS01E, 30 placebo). Diverse M. tuberculosis lineages were identified in both M72/AS01E and placebo recipients. No multidrug-resistant strains were detected. Genetic sequences corresponding to the antigenic components of M72/AS01E, showed low variation in pepA and high variation in PPE18. However, no apparent preferential distribution of variants was observed in M72/AS01E or placebo recipients. Cluster analyses identified 10 genomic clusters with isolates from >1 participant, illustrating complex transmission dynamics and potential of co-infection by multiple strains within individuals. CONCLUSION: This descriptive analysis showed no apparent preferential distribution of local M. tuberculosis strains in M72/AS01E or placebo recipients. These results support the continued development of this candidate vaccine.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wattiau P, Omar SV, Joseph L, et al. Genetic characterization of M. tuberculosis isolates from participants in a Phase 2b randomized trial evaluating the M72/AS01E tuberculosis candidate vaccine. J Infect Dis. 2026. PMID: 42663178. doi:10.1093/infdis/jiag428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。